How long do retatrutide side effects last?
In the phase 3 monotherapy trial, the common gastrointestinal events were generally mild to moderate and subsided over time. No exact duration is given.
Short answer
In the phase 3 monotherapy trial, the common gastrointestinal events were generally mild to moderate and subsided over time. No exact duration is given.[1]
In the phase 2 obesity trial, dose-dependent heart-rate increases peaked at 24 weeks and declined afterwards.[2]
What changed how long and how much
Gastrointestinal events were dose-related and partially mitigated by a lower starting dose in the phase 2 obesity trial.[2]
A class-wide review places nausea, vomiting, diarrhoea and constipation mainly at initiation and dose escalation.[3]
In the monotherapy trial, 2-5% stopped retatrutide because of adverse events, against 0% on placebo.[1]
More questions on Retatrutide
More on Retatrutide
Sources
- 1Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
- 2Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 3Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026PMID 42808923Accessed 2 Oct 2026
Found an error? Report a correction.